3 active not recruiting, 2 completed, 2 recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Active not recruiting 2, Recruiting 2 |
Follow Recurrent Hairy Cell Leukemia: new trials by email Literature Review of Recurrent Hairy Cell Leukemia trials Research Report on Recurrent Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2024-12-16 | 2026-09-09 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2013-04-30 | 2026-09-15 |
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Cladribine, Laboratory Biomarker Analysis, Rituximab - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2004-06-10 | 2026-06-11 |
Leukemia, Hairy Cell (7) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Mastocytosis, Systemic (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, Lymphoid (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Pathologic Processes (3)
Biopsy (3) · Specimen Handling (3) · CT-P10 (2) · Cladribine (2) · Rituximab (2) · Acetaminophen (1) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dexamethasone (1) · Diphenhydramine (1) · Etoposide (1) · High-Energy Shock Waves (1) · Ibuprofen (1)
National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Joseph Tuscano (1) · M.D. Anderson Cancer Center (1)
United States (7)
Farhad Ravandi-Kashani (1) · Ibrahim T Aldoss (1) · Joseph M Tuscano (1) · Kerry A Rogers (1) · Robert J Kreitman (1) · Seema A Bhat (1) · Tanya Siddiqi (1)
PMID 21821712, PMID 33754642, PMID 34492703, PMID 35622074, PMID 41980020
P30CA033572 (2), UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), P30CA093373 (1), U01CA076576 (1)